2018's Expo will include the New Products Showcase which gives exhibitors the opportunity to highlight their newest lines while getting additional exposure for their products at Global Pet Expo. It is also an opportunity for key international and domestic buyers to see what's new and exciting in the industry. The New Product Showcase receives a great deal of interest at the Show as well as coverage in numerous trade publications. With hundreds of entries, this is the largest new products showcase at any pet product industry trade show in the world.ABOUT CESAR MILLAN New York Times best-selling author and twice Emmy-nominated television personality Cesar Millan has earned a trusted reputation as the preeminent authority in the field of dog rehabilitation. With more than 25 years of experience working with canines, Millan uses a philosophy of trust, respect and love to rehabilitate aggressive, frightened and neurotic dogs while educating owners on how their own behavior affects their pets. Millan extends his reputation in dog training and care through retail and home entertainment products, books and Cesarsway.com, which have become top resources for dog help and advice; through the ongoing work of the Cesar Millan Pack Project; and through connecting with TV audiences via his television series, Cesar Millan's Dog Nation. For more information, visit www.cesarsway.com. Follow Cesar on Facebook (cesar.millan), Twitter (@cesarmillan) and YouTube (CesarMillan). ABOUT AVIVAGEN Avivagen Inc. is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About Vivamune™ Health Chews (Vivamune) Vivamune is an all-in-one chew that can dramatically simplify a pet's supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient: OxC-beta™ compound, Vivamune targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune is available for sale in the United States. For more information, visit www.vivamunehealth.com. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "aim", "anticipate", "appear", "believe", "consider", "could", "estimate", "expect", "if", "intend", "goal", "hope", "likely", "may", "plan", "possibly", "potentially", "pursue", "seem", "should", "whether", "will", "would" and similar expressions. Statements about the anticipated response from retailers and distributors at Global Pet Expo set out in this news release are forward-looking statements. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, the following: whether Avivagen will receive a strong response from retailers and distributors at Global Pet Expo, whether Vivamune can deliver the benefits described in this press release to any or all dogs, if at all, if Avivagen can accelerate market access and the commercial uptake of its Vivamune Health Chews supplement, and other risks and uncertainties outlined in Avivagen's most recent securities filings. These risks and uncertainties that could cause actual results or events to differ materially from current expectations. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For more information: Avivagen Inc.Drew BasekDirector of Investor Relations100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: email@example.comKym AnthonyChairman & Interim CEO100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164Website: www.avivagen.com Copyright © 2018 Avivagen Inc. OxC-beta™ and Vivamune™ are trademarks of Avivagen Inc.